Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
234.2 EUR | -2.21% |
|
-3.94% | -18.82% |
06-28 | Would you like some more inflation? | ![]() |
06-28 | Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU | MT |
Business Summary
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sales per Business
DKK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Antibody Therapeutics
100.0
%
| 14,595 | 100.0 % | 16,474 | 100.0 % | +12.87% |
Sales per region
DKK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Denmark
97.4
%
| 14,595 | 100.0 % | 16,053 | 97.4 % | +9.99% |
United States
2.3
%
| 0 | 0.0 % | 380 | 2.3 % | - |
Japan
0.2
%
| 0 | 0.0 % | 41 | 0.2 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 31/12/98 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 31/12/06 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 22/03/20 |
Tahamtan Ahmadi
CTO | Chief Tech/Sci/R&D Officer | 51 | 31/12/16 |
Marisol Peron
IRO | Public Communications Contact | - | 10/03/19 |
Human Resources Officer | 46 | - | |
Judith Klimovsky
PRN | Corporate Officer/Principal | 67 | 08/02/17 |
Martine van Vugt
PRN | Corporate Officer/Principal | 71 | 31/12/00 |
General Counsel | 63 | 31/12/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 31/12/16 |
Director/Board Member | 73 | 31/10/03 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 31/12/15 |
Director/Board Member | 59 | 28/03/22 | |
Director/Board Member | 57 | 31/12/14 | |
Director/Board Member | 73 | 31/12/14 | |
Director/Board Member | 51 | 28/03/19 | |
Martin Schultz
BRD | Director/Board Member | 49 | 31/12/21 |
Director/Board Member | 50 | 31/12/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 66,136,909 | 65,150,443 ( 98.51 %) | 981,465 ( 1.484 %) | 98.51 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
GENMAB A/S 3.79% | 2,508,013 | 3.79% | 707,063,489 $ |
Company contact information
![address Genmab A/S(GE9)](https://cdn.zonebourse.com/static/address/111963185.png)
Sector
Sales per region
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B | |
+116.20% | 10.8B |
- Stock Market
- Equities
- GMAB Stock
- GE9 Stock
- Company Genmab A/S